Clinical trials: Target Lesion
Alzheimer Disease
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
The study is a 24-week, randomized, double-blind, multi-site, placebo-controlled study in participants with mild cognitive impairment (MCI) or early dementia due to Alzheimer's disease (AD).
- Trial name
- PEGASUS (NCT03533257)
- Testing
- AMX0035
- Where
- 11 sites in United States
- Volunteers
- 95 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Psoriatic Arthritis (PsA)
Psoriatic Arthritis Treat to Target vs. Usual Care
Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care.
- Trial name
- PRC-05-2011 (NCT01692912)
- Testing
- Intensive Care
- Where
- 4 sites in Canada
- Sponsor
- Pope Research Corporation
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with…
- Trial name
- NCT00612040
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 33 sites in United States, Australia and 3 more
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with…
- Trial name
- OPTIMA (NCT07034690)
- Testing
- Educational Material, Standard of care
- Where
- United Arab Emirates
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Arrest, Renal Failure
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
To evaluate the effect of automated recording on frequency of recorded scores, number of automated notifications and serious events.
- Conditions
- Cardiac Arrest, Renal Failure, Respiration Failure, Myocardial Infarction
- Trial name
- NCT02973243
- Testing
- Automatic RR Measurement
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- Philips Healthcare
Hypertension
An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach…
- Trial name
- NCT02969265
- Testing
- Amlodipine, TCV-116CCB
- Where
- 25 sites in China
- Sponsor
- Takeda
Essential Hypertension
Olmesartan as an add-on to Amlodipine in Hypertension
This study is to test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with amlodipine alone
- Trial name
- NCT00220233
- Testing
- olmesartan medoxomil, amlodipine, hydrochlorothiazide
- Where
- 5 sites in Germany
- Volunteers
- 632 people
- Sponsor
- Sankyo Pharma Gmbh
Coronary Artery Disease
Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)
The study aims to further assess the safety, efficacy and the performance of its delivery system of FIREHAWK rapamycin-eluting stent up to five years.
- Trial name
- NCT01412164
- Testing
- FIREHAWK biodegradable polymer rapamycin-eluting stent
- Where
- China
- Volunteers
- 730 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Healthy
PET Study of Repeated ASN51 in Healthy Volunteers
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs)…
- Trial name
- NCT05725005
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
study evaluates a biomarker-guided strategy to assign adults with refractory SLE to autologous CAR-T therapy targeting either CD19 or BCMA.
- Trial name
- SELECT-SLE (NCT07523542)
- Testing
- Autologous anti-CD19 CAR-T cells, intravenous single infusion at protocol-defined dose level (1 x 10^6 or 3 x 10^6 CAR-positive viable T cells/kg)., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Biotech
Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
- Trial name
- NCT07510802
- Testing
- Dual-target CAR-NK cells, Lymphodepleting, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Schizophrenia
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
- Trial name
- NCT04787302
- Testing
- CVL-231
- Where
- 2 sites in United States, Belgium
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs
This trial is conducted in Europe. This is a clinical trial investigating the effectiveness and the safety of using biphasic insulin aspart 30 both for initiation and intensification of insulin treatment in type 2 diabetes.
- Trial name
- IMPROVE (NCT00537277)
- Testing
- biphasic insulin aspart
- Where
- Turkey (Türkiye)
- Volunteers
- 161 people
- Sponsor
- Novo Nordisk A/S
Respiratory Disease
QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study
This study will evaluate the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method
- Trial name
- NCT05733559
- Testing
- QIAstat-Dx® Respiratory Panel Plus (RPP)
- Where
- United Kingdom
- Volunteers
- 565 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Atherosclerotic Cardiovascular Disease
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice
The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice.
- Trial name
- NCT07615166
- Testing
- Alirocumab 150 mg, Inclisiran
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- Sanofi
Ischemic Heart Disease, Coronary Stenosis
RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia
The purpose of this study is to document the safety and overall clinical performance of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a patient population with long lesion(s) and/or dual vessels requiring…
- Conditions
- Ischemic Heart Disease, Coronary Stenosis, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- R-A (NCT01132456)
- Testing
- Drug eluting stent treatment
- Where
- India
- Volunteers
- 312 people
- Sponsor
- Medtronic Vascular
Parkinson Disease
Utilization of Target Ranges to Treat Persons With Parkinson's Disease by Objective Measurement Using the PKG
The main objective of this study is to evaluate whether persons with Parkinson's disease (PwP) whose Parkinson's disease (PD) symptoms are uncontrolled have improved clinical patient outcomes and quality of life when managed with…
- Trial name
- TARGET-PwP (NCT04381065)
- Testing
- Personal KinetiGraph® (PKG®) System, Personal KinetiGraph® (PKG®) Watch
- Sponsor
- Global Kinetics Corporation
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT00982644)
- Testing
- insulin degludec, insulin glargine
- Where
- 187 sites in United States, Austria and 13 more
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Healthy Participants
Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51
This is a phase 1, open-label, positron emission tomography (PET) study in healthy adult participants to determine the relationship between plasma concentration and brain target occupancy of ASN51 following a single oral dose.
- Trial name
- NCT06390098
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
High Blood Cholesterol
An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon
This was a multicenter survey of patients who were on lipid -lowering pharmacological treatment in 2 Levant countries namely Jordan and Lebanon.
- Trial name
- CEPHEUS (NCT01614561)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca